Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430273 | 0.83 | PDE4A (0.46) | ALDH1A1HSD17B10TSHRHIF1ATDP1 | |
| SCHEMBL29583446 | 0.83 | PDE4A (0.46) | ALDH1A1HSD17B10TSHRHIF1ATDP1 | |
| SCHEMBL15310451 | 0.83 | IDO1 (0.42) | IDO1ALDH1A1CYP3A4HSD17B10HPGD | |
| SCHEMBL11843814 | 0.79 | IDO1 (0.42) | IDO1ALDH1A1CYP3A4HSD17B10HPGD | |
| SCHEMBL3043085 | 0.78 | PDE4A (0.48) | ALDH1A1CYP3A4HSD17B10HPGDTSHR | |
| SCHEMBL901034 | 0.78 | PDE4A (0.48) | ALDH1A1CYP3A4HSD17B10HPGDTSHR | |
| SCHEMBL9778172 | 0.77 | IDO1 (0.45) | IDO1ALDH1A1CYP3A4HSD17B10HPGD | |
| Alcohol SCHEMBL28499385 | 0.76 | IDO1 (0.48) | IDO1ALDH1A1CYP3A4HSD17B10HPGD | |
| SCHEMBL15033126 | 0.76 | ALDH1A1 (0.41) | ALDH1A1HSD17B10HPGDTSHRCASP1 | |
| SCHEMBL18421692 | 0.75 | PTK2 (0.41) | ALDH1A1HSD17B10ALOX15CASP7HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876470-A | Method for synthesizing quinazolinone compound under nonmetal catalysis without additive | 中国科学院大连化学物理研究所 | 2021-06-01 | — | — | CN | claimed |
| CN-116375641-B | C3-phenoxy substituted quinoline compound and synthetic method and application thereof | 杭州师范大学 | 2025-01-03 | — | — | CN | disclosed |
| CN-116375641-A | C3-phenoxy substituted quinoline compound and synthetic method and application thereof | 杭州师范大学 | 2023-07-04 | — | — | CN | disclosed |
| CN-112876470-B | Method for synthesizing quinazolinone compound under nonmetal catalysis without additive | 中国科学院大连化学物理研究所 | 2022-08-30 | — | — | CN | disclosed |
| CN-112876470-A | Method for synthesizing quinazolinone compound under nonmetal catalysis without additive | 中国科学院大连化学物理研究所 | 2021-06-01 | — | — | CN | disclosed |
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMECEUTICAL INC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMECEUTICAL INC (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3268355-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | MERCK SHARP & DOHME LLC | 2009-01-15 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| CN-101312957-A | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) | NOVARTIS AG (CH) | 2008-11-26 | — | — | CN | disclosed |
| EP-1973546-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Merck & Co., Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007081570-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | IDO1 4464/4885ALDH1A1 3603/4885CYP3A4 763/4885 |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | IDO1 192/4885ALDH1A1 2398/4885CYP3A4 3432/4885 |
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | IDO1 3713/4885ALDH1A1 1342/4885CYP3A4 3339/4885 |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | IDO1 3713/4885ALDH1A1 1342/4885CYP3A4 3339/4885 |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | IDO1 3713/4885ALDH1A1 1342/4885CYP3A4 3339/4885 |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | IDO1 3713/4885ALDH1A1 1342/4885CYP3A4 3339/4885 |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | CETP, APOB, MTTP | IDO1 4666/4885ALDH1A1 1674/4885CYP3A4 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.